Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval

(Reuters) -Alnylam Pharmaceuticals said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug Administration declined to approve the medication despite a favorable recommendation from its advisers. The regulator, in its so-called complete response letter, said the drug patisiran did not meaningfully improve the condition of patients with heart muscle issues or cardiomyopathy caused by ATTR amyloidosis, characterized

Related Keywords

Bengaluru ,Karnataka ,India ,United States ,Pooja Desai ,Myles Minter ,William Blair ,Pfizer ,Drug Administration ,Reuters ,Alnylam Pharmaceuticals ,Luca Issi ,Mariam Sunny ,Food And Drug Administration ,Sttr ,Adult Patients ,Amyloid Cardiomyopathy ,Ereditary Attr Amyloidosis ,Cardiomyopathy ,